Project Beacon is a social benefit organization focused on helping to increase the capacity, availability, accessibility, and affordability of COVID-19 testing in Massachusetts. We have no profit motive and any excess revenues over costs will be used to support public needs or, at the end of the project, donated to charity.
In March 2020, the Broad Institute of MIT and Harvard began performing COVID-19 testing for Massachusetts and the surrounding region with a focus on important state needs. By early August, it had completed more than 450,000 tests. While some uses can be supported by the Broad testing lab directly, other uses need "externally facing" services.
Project Beacon was launched by F-Prime Capital, GV, and Broad Institute to provide assistance with these externally facing services, such as:
Project Beacon is working to support a range of organizations, including colleges and universities, public K-12 schools, congregate care providers, not-for-profits, companies, and other institutions.
We are particularly focused on serving public needs and promoting equitable access. Any excess revenues generated by Project Beacon will be used to support public needs or, at the end of the project, donated to charity.
Defeating COVID-19 will ultimately require a range of solutions, drawing on the expertise of academia, biotech, the private sector, and the government. Project Beacon aims to help in this vital challenge.
In founding Project Beacon, F-Prime Capital, GV, The Broad Institute of MIT and Harvard were motivated by the desire to support significantly increased testing to help keep Massachusetts safe. Recognizing that defeating COVID-19 would require the brainpower, creativity, tools, and resources of individuals from across many disciplines, including the scientific community, the biotech world, the private sector, and the government, the organizations decided to leverage their resources and their networks to create Project Beacon.
Broad Institute of MIT and Harvard was launched in 2004 to improve human health by using genomics to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies.
Broad Institute is committed to meeting the most critical challenges in biology and medicine. Broad scientists pursue a wide variety of projects that cut across scientific disciplines and institutions.
F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies. With over two billion dollars under management and a global portfolio of more than 190 companies, we champion those dedicated to creating positive change in the world.
F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com and follow us on Twitter and LinkedIn.
GV provides venture capital funding to bold new companies. Across the fields of life science, enterprise technology, consumer products and services, and frontier technology, GV's portfolio companies aim to improve lives and transform industries. GV's team of world-class engineers, designers, physicians, scientists, marketers, and investors work together to provide startups exceptional support.
Launched as Google Ventures in 2009, GV is the venture capital arm of Alphabet, Inc. GV helps startups interface with Google, providing unique access to the world’s best technology and talent.
GV has more than $5 billion under management, and is headquartered in Mountain View, California, with offices in San Francisco, Boston, New York, and London.
Our strategic vendors assist in support testing efforts, from running testing sites, to providing essential supplies, to processing COVID-19 tests, and include:
Our partners provide important advisory support, and include: